


# The ICSI Story To Infinity and Beyond

**Gianpiero D Palermo, MD, PhD, FACOG**

*Ronald O. Perelman & Claudia Cohen  
Center for Reproductive Medicine  
Weill Cornell Medicine  
New York, New York*

# Assisted Reproduction





# First ICSI Pregnancy

Age

38

Oocyte harvested

14 (12 MII)

SUZI

ICSI

Injected

11

1

No fert

1 (2PN)

24 hours later


1 (4 cell, 20% fragments)

Replacement


Pregnancy

**Delivery 46,XY**  
**January 14, 1992**

# Infertility Indications



# Evaluation of Male Partner



# Azoospermic Men

- Autosomal: 126

6 - translocation

21 - inversions

3 - deletion

54 - 46,XY \_\_\_ qh(+)

(chx 1,9,15,16)

42 - Others

- Gonosomal: 99

64 - Klinefelter's Syndrome

49 - 47,XXY

12 - 46,XY/47,XXY

2 - 47,XXY/48,XXXY

1 - 47,Xi(Xq)Y

14 - 46,XY (delYq)

3 - 45,X/46,XY

2 - 45,X/46,XY,q-



7 - 47,XYY

9 - Others

*Nakamura et al., Int J Urol 2001*

*Hamada et al., Clinics, 2013*

*Mazzilli et al., Asian J Androl 2022*





Concentration (x10 <sup>6</sup> /ml)	Yq del (%)
≥ 5	0/41
< 5	1/42 (2.4)
< 1	6/103 (5.8)
0	69/834 (8.2)

No. of	Ejaculated	Testicular
Cycles	14	11
Patients	6	7
Density (x 10 <sup>6</sup> /ml)	2.5	0.0003
Oocytes inseminated	149	102
Oocytes fertilized (%)	80 (53.7)	42 (41.2)
Clinical pregnancies	5 (35.7)	4 (36.4)

Hopps et al., Hum Reprod, 2003  
 Choi et al., Fertil Steril, 2004  
 Katagiri et al., RBMO, 2004  
 Zhou, et al., Asian J Androl., 2021









# Cornell ART



1993-2022  
Cycles 60,779


# ICSI Prevalence

2012 to 2022  
 $n = 26,874$



# 44,585 ICSI Cycles

September 1993 – August 2022



# ICSI

## Ejaculated Spermatozoa

---

<b>Cycles</b>		<b>40,547</b>
<b>Mean maternal age (<math>\pm</math> SD)</b>		<b>38.2 <math>\pm</math> 5</b>
<b>Semen parameters</b>	<b>Normal</b>	<b>6,777</b>
	<b>Abnormal*</b>	<b>33,742</b>

---

\*WHO, 2010

# Survival and Fertilization Characteristics

## Ejaculated Spermatozoa


### MII Injected

$n = 345,323$



### Fertilization patterns

$n = 336,164$




# Semen Origin and ICSI Outcome

Semen Origin	Cycles	Fertilization (%)	Clinical Pregnancies (%)*
Ejaculate	37,751	243,768/322,916 (75.5)	13,966 (37.0)
Electroejaculate	88	662/894 (74.0)	40 (46.0)
Retrograde	64	439/575 (76.3)	23 (36.0)

\*Includes only cycles with fresh transfer

# Male Infertility Indications





# ICSI and Azoospermia




---

<b>Cycles</b>	<b>3,417</b>
<b>Maternal age (M <math>\pm</math> SD)</b>	<b>36.4 <math>\pm</math> 5</b>
<b>Epididymal spermatozoa</b>	<b>1,364</b>
<b>Testicular spermatozoa</b>	<b>2,053</b>

---

# Obstructive Azoospermia

- Congenital (e.g., CBAVD)
- Acquired (e.g., infection, trauma)




# MESA

	Obstruction	
	Congenital	Acquired
<b>Cycles</b>	<b>604</b>	<b>643</b>
<b>Density (x 10<sup>6</sup>/ml ± SD)</b>	<b>27.6 ± 45</b>	<b>16.8 ± 26</b>
<b>Motility (M ± SD)</b>	<b>8.2 ± 12</b>	<b>18.3 ± 15</b>
<b>Morphology (M ± SD)</b>	<b>1.2 ± 2</b>	<b>1.0 ± 2</b>
<b>Fertilization (%)</b>	<b>4,411/6,118 (72.1)*</b>	<b>3,991/5,720 (69.8)*</b>
<b>Clinical pregnancies (%)</b>	<b>319 (52.8)†</b>	<b>268 (41.7)†</b>

\* $\chi^2$ , 2x2, 1 df, Effect of the etiology on fertilization rate,  $P = 0.01$

† $\chi^2$ , 2x2, 1 df, Effect of the etiology on clinical pregnancy rate,  $P = 0.0005$











# Testicular Sampling

	No. of biopsies
• Obstructive Azoospermia	311
• Non-Obstructive Azoospermia	2,693
Spermatozoa present (%)	1664 (61.8)

# Non-Obstructive Azoospermia


- Hypospermatogenesis

49.4%



- Sertoli cell only

26.6%



# TESE

	Azoospermia	
	Obstructive	Non-obstructive
Cycles	310	1,677
Density (x 10 <sup>6</sup> /ml ± SD)	2.2 ± 7	0.8 ± 7
Motility (M ± SD)	3.3 ± 8	3.6 ± 13
Morphology (M ± SD)	0	0
Fertilization (%)	1,841/2,782 (66.2)*	8,279/17,287 (47.9)*
Clinical pregnancies (%)	130 (42.5) <sup>†</sup>	598 (35.7) <sup>†</sup>

\* $\chi^2$ , 2x2, 1 df, Effect of etiology of azoospermia on fertilization rate,  $P < 0.00001$

<sup>†</sup> $\chi^2$ , 2x2, 1 df, Effect of the etiology on clinical pregnancy rate,  $P < 0.05$



# Klinefelter Syndrome

No. of (%)

---

Testicular biopsies

348

with sperm retrieved

215 (61.8)

Oocyte fertilized/injected

1,269/2,651 (47.9)

Deliveries

81 (39.5)

Children

99

---

53 boys, 46 girls

*Updated from Palermo et al., 1998*




**Fertility and Sterility®**

# **Identification and treatment of men with phospholipase C $\zeta$ -defective spermatozoa**

Stephanie Cheung, B.Sc., Philip Xie, B.Sc., Alessandra Parrella, M.Sc., Derek Keating, B.A.,  
Zev Rosenwaks, M.D., and Gianpiero D. Palermo, M.D., Ph.D.

Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York

# Study Design



# Oocyte-Related OAD PLCζ presence

No. of (%)	Control	Modified Superovulation	
Couples	52	52	105
Cycles			
Maternal age (M yrs±SD)		33.4±3	
Oocytes Retrieved	456		1120
Paternal age (M yrs±SD)		35.7±5	
MII Oocytes	334 (73.2)		796 (71.1)
Fertilization	7 (2.1)*		470 (59.0)*
Cycles with ET	6		91
Clinical Pregnancy (+FHB)	0		30 (32.9)
Deliveries	—		25

\* $\chi^2$ , 2x2, 1 df,  $P<0.0001$

*Cheung et al., 2020 Fertil Steril*  
*Cheung et al., 2022 Fertil Steril in press*

# Spe

No. of (%)

Couples  
Cycles

Maternal age (M)  
Oocytes Retrieval  
Paternal age (M)  
MII Oocytes

Fertilization

Cycles with ET

Clinical Pregnancies

Deliveries

absence

AGT

43

404

323 (79.9)

136 (42.1)\*

25

9 (36.0)

6

\* $\chi^2$ , 2x2, 1 df,  $P < 0.05$



Cheung et al., 2020 Fertil Steril  
Cheung et al., 2022 Fertil Steril in press



# Sperm Gender Selection

## *Semen Parameters (selected)*


---

Concentration (M x10 <sup>6</sup> /ml±SD)	24.3±14
Motility (M%±SD)	94.5±3
Morphology (%±SD)	3.8±1

## *Sperm Gender Enrichment*

X-bearing spermatozoa (%±SD)	81.6±1
Y-bearing spermatozoa (%±SD)	80.8±2

---



# Pregnancy Outcome *Female*

---

Couples/Cycles	52/70
Maternal age (M yrs $\pm$ SD)	38.9 $\pm$ 3
Paternal age (M yrs $\pm$ SD)	41.7 $\pm$ 4



# Pregnancy Outcome *Male*

---

Couples/Cycles

46/50


Maternal age (M yrs $\pm$ SD)

37.3 $\pm$ 4

Paterna

*Clinicaltrials.gov NCT05500573*

# Sperm DNA Organization



*Adapted from Doug Carrell, 2012*

# Perspectives on the assessment of human sperm chromatin integrity

Gianpiero D. Palermo, M.D., Ph.D., Queenie V. Neri, M.Sc., Tyler Cozzubbo, B.Sc., and Zev Rosenwaks, M.D.

The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York, New York

*Palermo et al., 2014 Fertil Steril*

Apoptosis plays a significant role in regulating germ cell development by removing damaged germ cells from seminiferous tubules, thereby safeguarding the genome of a given species. The unique chromatin-packing process of the spermatozoon has important implications for both the development of male infertility screening tests and understanding of sperm chromatin characteristics, which may affect assisted reproductive technology outcomes. Sperm deoxyribonucleic acid (DNA) integrity tests have been proposed as a means to assess male gamete competence. Although these assays are currently gaining popularity, and are more often used as a supplement to traditional semen analysis, the point at which DNA damage occurs during spermiogenesis, and to what degree, remains to be elucidated. Here, we examined current studies of DNA fragmentation, to understand its origin and import, as well as its impact on pre- and post-implantation development. As the DNA fragmentation index is strongly correlated with the motility characteristics of a semen specimen, controlling for this factor may be helpful. Utilization of more sensitive assays, possibly on the actual spermatozoa used for insemination, may generate healthier conceptuses. (Fertil Steril® 2014;102:1508–17. ©2014 by American Society for Reproductive Medicine.)

**Key Words:** ICSI, sperm DNA fragmentation, follow-up of children, TUNEL, SCSA, SCD, COMET

---

**Discuss:** You can discuss this article with its authors and with other ASRM members at <http://fertstertforum.com/palermog-human-sperm-chromatin-integrity/>




Use your smartphone to scan this QR code and connect to the discussion forum for this article now.\*

\* Download a free QR code scanner by searching for “QR scanner” in your smartphone’s app store or app marketplace.

# SCSA and Motility

n=179



# Alternative Treatment





# A treatment approach for couples with disrupted sperm DNA integrity and recurrent ART failure

Alessandra Parrella<sup>1</sup> · Derek Keating<sup>1</sup> · Stephanie Cheung<sup>1</sup> · Philip Xie<sup>1</sup> · Joshua D. Stewart<sup>1</sup> · Zev Rosenwaks<sup>1</sup> · Gianpiero D. Palermo<sup>1</sup>

Received: 3 May 2019 / Accepted: 23 July 2019 / Published online: 16 August 2019  
© The Author(s) 2019

# Semen Parameters

## 69 Patients


	Raw	Selection	
		Density Gradient	Microfluidics
Volume (mL)	$2.2 \pm 1^*$	$0.5 \pm 0^*$	$0.5 \pm 0^*$
Concentration (M $\times 10^6$ /ml $\pm$ SD)	$28 \pm 34^\dagger$	$17.2 \pm 22^\dagger$	$8.4 \pm 13^\dagger$
Motility (M% $\pm$ SD)	$33.6 \pm 14^\ddagger$	$59.5 \pm 34^\ddagger$	$97.0 \pm 1^\ddagger$
Morphology (M% $\pm$ SD)	$2.1 \pm 1^\S$	$1.8 \pm 1^\S$	$3.2 \pm 1^\S$

\*†‡ Paired t-test, 1 df,  $P < 0.0001$




# Spermatozoa Motility


Raw




Density Gradient



Microfluidics



# Sperm Chromatin Fragmentation




# MFSS & Fresh ET

No. of	Selection	
	Density Gradient	Microfluidics
Couples	80	
Cycles	191	90
Maternal Age (M $\pm$ SD)	37.8 $\pm$ 3	37.9 $\pm$ 3
Paternal Age (M $\pm$ SD)	42.8 $\pm$ 6	43.2 $\pm$ 6
Fertilization rate	1172/1761 (66.6)	523/768 (68.1)

# Clinical Outcome



## Fresh ET






# Patterns


0




1




2




3



4



# Sperm Chromatin Fragmentation



# MFSS & PGT-A


No. of	Selection	
	Density Gradient	Microfluidics
Couples	85	
Cycles	88	86
Maternal Age (M±SD)	36.2±5	36.9±5
Paternal Age (M±SD)	36.9±7	37.5±7
Fertilization rate	848/1274 (66.6)*	949/1223 (77.6)*

\* $P<0.00001$


# Euploidy Rates

*\*P* < 0.0001

Density Gradient




Microfluidics






# Clinical Outcome


## PGT-A



# IVF vs ICSI



# Maternal Age & ICSI Deliveries



## ICSI Indications



# Global ART in 2014


76 Countries

	IVF	ICSI	Total
Cycles	374,843 (37.7)	619,811 (62.3)	994,654
Newborns	165,518	273,521	439,039

*ICMART, Chambers, et al., 2021 Human Reproduction*

RESEARCH ARTICLE

# Genetic and epigenetic profiling of the infertile male

**Stephanie Cheung, Alessandra Parrella, Zev Rosenwaks, Gianpiero D. Palermo \***


The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, New York, United States of America

\* [gdpalerm@med.cornell.edu](mailto:gdpalerm@med.cornell.edu)


## Abstract

Evaluation of reproductive quality of spermatozoa by standard semen analysis is often inadequate to predict ART outcome. Men may be prone to meiotic error and have higher proportion of spermatozoa with fragmented chromatin, capable of affecting the conceptus' health. In men with unexplained infertility, supplementary tests may be pivotal to gain insight into the paternal contribution to the zygotic genome. A total of 113 consenting men were






# Spermiogenesis





# Spermatogenesis Prediction

*RNAseq*



Ng et al., 2022 personal communication

# Spermatogenesis Prediction

*DNAseq*

+Sperm		TRPC1	IGSF11-AS1	SPZ1	NEU1	SMKR1	C10orf62	TPTE2	TMC05B
	PT#1	--	ns	--	syn	--	ms	--	--
	PT#2	--	ns	--	syn	--	ms	--	--
-Sperm	PT#3	--	ns	--	syn	--	ms	--	--
	PT#4	ms	ns	fs	fs	fs	ms	fs	--
	PT#5	ms	ns	fs	fs	fs	ms	fs	--
	PT#6	ms	ns	fs	fs	fs	ms	fs	--
	PT#7	ms	ns	fs	fs	fs	ms	fs	--
	PT#8	ms	ns	fs	fs	fs	ms	fs	--
	PT#9	ms	ns	fs	fs	fs	ms	fs	--
	PT#10	ms	ns	fs	fs	fs	ms	fs	--

ms: missense

ns: nonsense

fs: frameshift

syn: synonymous

Gene	Ch	Function
TRPC1	3	Transient receptor potential non voltage-channel 1, expressed in adult heart, brain, testis, ovaries (Wes et al., 1995 PNAS)
IGSF11-AS1	3	Long non-coding RNA, downregulated in infertile male (Zhou and Wang, 2020 JIMR)
SPZ1	5	Regulation of cell proliferation/differentiation during spermatogenesis (Horowitz et al., 2005 Mol Hum Reprod)
NEU1	6	Neuraminidase, acrosomal reaction and capacitation (Ma et al., 2012 J Biol Chem)
SMKR1	7	Spermatid development, testis-specific in ovine species (Hodge et al., 2021 Genes)
C10orf62	10	Spermatid development, testis-specific (Djureinovic et al., 2014 Hum Reprod)
TPTE2	13	Acts as a lipid phosphatase, candidate genes for severe sperm motility disorders (Oud et al., 2021 Hum Reprod)
TMC05B	15	Pseudogene, Testis-specific (Hong et al., 2018 BMC Genomics) & spermatid development in mouse (Yamase et al., 2019 PLoS One)


*Cheung et al., 2022 personal communication*

# Three-dimensional sperm surface reconstruction: a novel approach to assessing sperm morphology

Brian A. Levine, M.D., M.S.,<sup>a</sup> Jeremy Feinstein, M.Eng.,<sup>b</sup> Queenie V. Neri, M.Sc.,<sup>a</sup> Dan Goldschlag, M.D.,<sup>a</sup> Zev Rosenwaks, M.D.,<sup>a</sup> Serge Belongie, M.S., Ph.D.,<sup>c</sup> and Gianpiero D. Palermo, M.D., Ph.D.<sup>a</sup>

<sup>a</sup> The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical College, New York;

<sup>b</sup> Department of Computer Science, College of Engineering, Cornell University, Ithaca; and <sup>c</sup> Cornell Tech, Cornell University, New York, New York



# Rheotaxis-based separation of sperm with progressive motility using a microfluidic corral system

Meisam Zaferani<sup>a</sup>, Soon Hon Cheong<sup>b</sup>, and Alireza Abbaspourrad<sup>a,1</sup>

*Zaferani et al., 2018 PNAS*


<sup>a</sup>Department of Food Science, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14853; and <sup>b</sup>Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

Edited by Howard A. Stone, Princeton University, Princeton, NJ, and approved July 3, 2018 (received for review January 15, 2018)

The separation of motile sperm from semen samples is sought after for medical infertility treatments. In this work, we demonstrate a high-throughput microfluidic device that can passively isolate motile sperm within corrals inside a fluid channel, separating them from the rest of the diluted sample. Using finite element method simulations and proposing a model for sperm motion, we investigated how flow rate can provide a rheotaxis zone in front of the corral for sperm to move upstream/downstream depending on their motility. Using three different flow rates that provided shear rates above the minimum value within the rheotaxis zone, we experimentally tested the device with human and bovine semen. By taking advantage of the rheotactic behavior of sperm, this microfluidic device is able to corral motile sperm with progressive velocities in the range of  $48\text{--}93\ \mu\text{m}\cdot\text{s}^{-1}$  and  $51\text{--}82\ \mu\text{m}\cdot\text{s}^{-1}$  for bovine and human samples, respectively. More importantly, we demonstrate that the separated fractions of both human and bovine samples feature 100% normal progressive motility. Furthermore, by extracting the sperm swimming distribution within the rheotaxis zone and sperm velocity distribution inside the corral, we show that the minimum velocity of the corralled sperm can be adjusted by changing the flow rate; that is, we are able to control the motility of the sepa-

biology. The factors that influence the journey of a sperm cell, which starts with ejaculation and ends with egg fertilization, are poorly characterized. Some efforts have investigated the response of sperm to external stimuli, like chemical gradients and fluid flow; such responses are generally referred to as “taxis” (10, 11). Researchers have also investigated the tail-beating patterns of sperm in different situations (12–14), as well as the molecular interactions between sperm and the female reproductive tract (1, 14–16). However, since the study of sperm in vivo is complicated by the existence of many environmental variables, such as pH, chemical gradients, and fluid flow (2, 10, 11), many questions about sperm behavior remain unanswered. The concurrent existence of these variables impedes our ability to gain better insight into sperm motion itself, which is a complex topic (17). Thus, the isolation of motile sperm in vitro (eliminating all external hydrodynamic velocity fields and dead sperm) could further assist the study of sperm locomotion. Additionally, isolating sperm in a particular region would enable the evaluation of an individual sperm’s biological and physiological responses to a specific chemical or physical factor (18). To summarize, any improvement toward separation and/or isolation of motile sperm










## BIOPHYSICS



# Strictures of a microchannel impose fierce competition to select for highly motile sperm

Meisam Zaferani<sup>1</sup>, Gianpiero D. Palermo<sup>2</sup>, Alireza Abbaspourrad<sup>1\*</sup>

Investigating sperm locomotion in the presence of external fluid flow and geometries simulating the female reproductive tract can lead to a better understanding of sperm motion during fertilization. Using a microfluidic device featuring a stricture that simulates the fluid mechanical properties of narrow junctions inside the female reproductive tract, we documented the gate-like role played by the stricture in preventing sperm with motilities below a certain threshold from advancing through the stricture to the other side (i.e., fertilization site). All the slower sperm accumulate below (i.e., in front of) the stricture and swim in a butterfly-shaped path between the channel walls, thus maintaining the potential for penetrating the stricture and ultimately advancing toward the fertilization site. Accumulation below the stricture occurs in a hierarchical manner so that dense concentrations of sperm with higher velocities remain closer to the stricture, with more sparsely distributed arrays of lower-velocity sperm lagging behind.








Flow direction






# Spherification






# Somatic Cell Nuclear Transfer and Haploidization



Control

Well 2



2.1 h



SCNT-CC

Well 4

1.1 h



Lee et al., 2022 Nature Commun Biol

# Conclusions

- ICSI is the ultimate treatment for male infertility
- ICSI is versatile and consistent
- ICSI remains a popular insemination method
- More information on the male gamete genome
- *In-Vitro* Gametogenesis will certainly require ICSI
- AI may present the next chapter



## NURSING STAFF

Victoria Nowesielski, RN  
 Christine Lu, RN  
 Juliana Shen, RN  
 Debra Henry, RN  
 Holly Nadal, RN  
 Hanna Murtaugh, RN  
 Devon Klauck, NP  
 Sarah Staube, RN  
 Sheri Fitzpatrick, RN  
 Siobahn Plunkett, RN  
 Susan Ng, RN  
 Christine Zotto, PA  
 Rodriq Stubbs, NP  
 Cheryl Sabatino, RN  
 Amy Prince, RN  
 Cindy Acosta  
 Deanna Armstrong  
 Rosanna Contreras  
 Jenny Soto

## NURSING RESEARCH

Rodriq Stubbs, NP  
 Mitasha Joseph, RN  
 Amy Humphreys, MPH

## PSYCHOLOGY

Laura Josephs, PhD  
 Elizabeth Grill, PsyD

## CLINICAL SCIENTISTS

Zev Rosenwaks, MD  
 Owen K. Davis, MD  
 Pak H. Chung, MD  
 Dan E. Goldschlag, MD  
 Hey-Joo Kang, MD  
 Isaac Kligman, MD  
 Samantha Pfeifer, MD  
 Glenn L. Schattman, MD  
 Steven D. Spandorfer, MD  
 Rony T. Elias, MD  
 David Reichman, MD  
 Alexis Melnick, MD  
 Nigel Pereira, MD  
 Joshua Stewart, MD  
 Gianpiero D. Palermo, MD, PhD

## EMBRYOLOGY

Nikica Zaninovic, PhD  
 Jiying Hao, MD  
 Richard Bodine  
 Zhen Ye, PhD  
 Samuel Jones  
 June Hariprashad  
 Rosa Robles  
 Ana Robles  
 Christopher Norberg  
 Ameeta Bahia  
 Qiansheng Zhan, MD, PhD

## REI FELLOWS

Nina Vyas, MD  
 Ashley Aluko, MD  
 Jasmyrn Johal, MD  
 Shelun Tsai, MD  
 Kelly McCarter, MD  
 Christopher Moutos, MD

## ADMINISTRATIVE STAFF

Terry Vazquez	Waleska Padillo
Julie Carty	Dee Giovannetti
Justine Witzke	Una Cullen
Helena Chicketano	Brenda Burgos
Angie Grullon	Carolina Morales
Eileen Garcia	Tamara Edme
Sandra Edwards	Tiffany Reid
Avery Black	Debra Lilienthal
Janine Jalac	Shanise Jackson
Letty Crespo	Jaresyss Gordon-Rey
Jennifer Clark	Adrienne Gomes
Evelyn Corey	Consuelo Serrano
Melanie Gerena	Jahaida Reyes
Raquel Mintah-Ellison	Tramaine Scott
Maureen Ennis	Jeanine Beudeker
Ty Chicketano	Luis Franco
Andres Castillo	Ian Prince
Diana Pak	Erica Luong
Victoria Camerron	Jane Huang
Rosangeli Russo	Jessica Gould

## STEM CELL DERIVATION LAB

Shahin Rafii MD  
 Nikica Zaninovic PhD  
 Daylon James PhD  
 Qiansheng Zhan MD, PhD  
 Kenny Chao

## ICSI & ANDROLOGY

Gianpiero D. Palermo, MD, PhD  
 Queenie Neri, PhD  
 Stephanie Cheung, MS  
 Philip Xie, BS  
 Olena Kocur, BA  
 Sydney Souness, BS  
 Mary McKnight, BS  
 Lily Ng, BS  
 Meryem Okumus, BS  
 Angela De Jesus, BS

## REPRODUCTIVE UROLOGY

Marc Goldstein, MD  
 Peter Schlegel, MD  
 Philip Li, MD  
 James Kashanian, MD

## PGD

Kangpu Xu, DVM, PhD  
 Ali Sharma, PhD  
 Jianwen Wei PhD  
 Joseph Marzouk  
 Benjamin Fang, BS  
 Xiaoe Qin

## ENDOCRINOLOGY

Daylon James PhD  
 Limor Man, MD  
 Inga Zhygalo  
 Jennifer Marino  
 Barbara Caiazza  
 Ritaben Patel  
 Zong-ying Liu  
 Carmen Torres



# The ICSI Story To Infinity and Beyond

**Gianpiero D Palermo, MD, PhD, FACOG**

*Ronald O. Perelman & Claudia Cohen  
Center for Reproductive Medicine  
Weill Cornell Medicine  
New York, New York*